% | $
Quotes you view appear here for quick access.

Boston Scientific Corporation Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • boulder_56 boulder_56 Jul 13, 2005 8:24 PM Flag

    Next stop $21. Down she goes

    be considerate of others feelings.
    you are far too angry and should show more
    compassion to the good things that BSX does.
    if earnings are down it is ok because everyone
    is trying their hardest and next quarter will
    be better...

    yeah f*cking right!!!


    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Are insiders shorting? This stock is looking terrible fundamentally and technically. I think there may be some kind of disaster here. The chart indicates a fall below $21.

    • (All investors want their stocks to turn out winners. So if a stock you buy heads south, you might hang on in hopes of a reversal. It's been a longtime leader and will come back, you reason. But if a turnaround never occurs, such hopes can erode your gains or even seriously damage your portfolio.

      That's why sell rules are just as important as buy rules. Always pay attention to warning signs, and cut your losses if a stock falls 7% to 8% below your initial buy price. Don't let hope tarnish that golden rule.

      If you don't contain a loss while it's small, it could quickly snowball into 20% or more. Your best tactic is to cut your losses and move onto another stock

      • 2 Replies to politicaldebate1
      • How much is this costing?? How long can they keep losing money?
        Natick, MA (June 21, 2005) -- Boston Scientific Corporation (NYSE: BSX) announced today that a jury in a patent infringement case in U.S. District Court in Delaware brought by Johnson & Johnson (NYSE: JNJ) against Boston Scientific has returned a verdict. The jury found that Boston Scientific's stents infringe a J&J patent and that the Libert� stent infringes a second J&J patent. Boston Scientific had challenged the validity of one of the patents, and the jury upheld the patent's validity. The jury only determined liability; monetary damages will be determined in a later trial.Bostin Scientific stated that it is disappointed in the jury's decision.

        Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a civil settlement agreement with the U.S. Department of Justice regarding the Department's investigation. The Company agreed to pay $74 million as part of the agreement. (OUCH)

        Boston Scientific Announces Worldwide Recall of Hemashield� VANTAGE� Peripheral Vascular Grafts.

        Natick, MA (June 27, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced that it is voluntarily recalling worldwide all Hemashield� VANTAGE� Vascular Grafts, which are used in peripheral procedures. No other Hemashield� products are affected by this recall. The Company is recalling all Hemashield VANTAGE Vascular Grafts manufactured in the last two years due to the potential of the device to fray or tear during suturing and the possibility that it could lead to post-operative complications. The Company is aware of three reported post-operative failures which occurred between three and seven days post-procedure

      • Makes no sense to sell a stock at it's bottom, which is driven only by potential negative legal results; if any of these go positive, UP SHE GOES...

    • Poor Pebble. You should get a new shrink. Does JNJ still cover your medical expenses? Or are you stuck with a state issued shrink. Too bad you lost your territory to a better BSX product and sales team. Even worse that you lost your mind over it. Sometimes life isn't fair.Poor Pebble.

22.71+0.13(+0.58%)May 31 4:01 PMEDT